COLUMBIA, MD and TORONTO, ON / ACCESSWIRE / November 29, 2018 / Medifocus Inc. (OTCQB : MDFZF and TSX-V: MFS)
is pleased to announce it has submitted for a new Patent Titled: "Thermodilatation and Thermocompression to Facilitate Targeted
Cluster Tissue Ablation and Immune Response". This Patent Pending invention will add to Medifocus' extensive patent portfolio of
already issued USA and International Patents.
This new patent was submitted on November 9, 2018 to the United States Patent and Trademark Office (USPTO). The authors of this
patent are: William W. Jow M.D., Stuart E. Katz M.D., Alan J. Fenn Ph.D. and John Mon. The patent utilizes thermocompression
technologies such as: Medifocus Prolieve® Transurethral Thermodilatation™ (TUTD™), Medifocus APA1000 Breast Cancer Focused
Microwave Treatment device and/or other thermocompression technologies to entrap pre-implanted high electric conductive material to
facilitate focused heating and/or activation of molecular therapeutics to cause Cluster Tissue Ablation. In addition, the enhanced
efficiency to local focused thermotherapy will facilitate the natural immune response within the entrapped microenvironment which
will further aid the ablation of both local and distant cancer sites.
Dr. William Jow, President and CEO of Medifocus Inc. added, "Filing this innovative patent is a testament to our commitment and
emphasis on Focal Therapy and will further the direction of our company toward Cancer Treatments. Focal therapies are ideal for
both early Prostate Cancer and early- and late-stage Breast Cancers as well as treatments of other benign and malignant lesions.
This invention can potentially be used with immunotherapeutic agents such as check point inhibitors to modulate the immune response
not only within the tumor microenvironment locally, but to open the pathways to distant sites. Facilitating local immune cell kill
and/or weakening tumor cell defense mechanism are in line with the current trend of cancer treatments."
About The Prolieve® Thermodilatation System
The Prolieve® Thermodilatation System offers potential relief to the millions of men who suffer from Benign Prostatic
Hyperplasia (BPH), a condition that becomes common as men age. About half of men over 50 have some enlargement of the prostate
gland, and this rises to about 90% among those over 70. As the prostate expands, it compresses or constricts the urethra, thereby
restricting the normal passage of urine. This can cause infection as well as bladder and kidney damage.
The Prolieve® system is a novel focused heat therapy product which utilizes a unique combination of "prostate directed" focused
heat energy in combination with a cooled, and pressurized "dilatation balloon" to achieve immediate and long-term relief of BPH
symptoms with very minimal treatment induced side effects after a 45 minute, in office out-patient procedure. The combined effect
of this "heat plus compression" therapy is twofold: first, the heat denatures the proteins in the wall of the urethra, causing a
stiffening of the opening created by the inflated balloon, forming a temporary biological stent. Second, the heat serves
effectively to kill off prostate cells outside the wall of the urethra, thereby creating sufficient space for the enlarged natural
opening.
About Medifocus, Inc.:
Medifocus, Inc. (TSXV-MFS, OTC-MDFZF) is a Biotechnology Company with a portfolio of medical technologies that utilize patented
Focal Thermal Technology to treat conditions ranging from Prostate Diseases to Breast Cancer. Its Prolieve® Thermodilatation™
System offers symptomatic relief to men with Benign Prostatic Hyperplasia (BPH) through a simple, 45-minute, in-office treatment.
Prolieve® is both FDA and Medicare approved for treating symptomatic BPH with over 100,000 cases performed in the U.S. alone, and
with proven long-term safety, efficacy and durability. Its APA 1000 Breast Cancer Treatment System was licensed from Massachusetts
Institute of Technology and developed by the Medifocus team. The Targeted Focal Thermotherapy has been demonstrated in Phase 2
clinical trials to offer significantly better tumor shrinkage in patients treated with the combined Chemothermal therapy compared
those treated with Chemotherapy alone. APA 1000 was also shown to be effective in reducing margin positivity among patients treated
with such thermotherapy prior to lumpectomy.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more details, please visit:
www.medifocusinc.com
www.prolieve.com
www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.
Company Relations: Medifocus, Inc. Tel: 410-290-5734
email to: info@medifocusinc.com
Forward-Looking Statements
This news release contains "forward-looking statements" and "forward-looking information", which may not be based on historical
facts. Forward-looking statements and forward-looking information, include, but are not limited to, information and statements with
respect to the benefit to Medifocus' future growth resulting from the acquisition of additional intellectual property rights,
additional treatment possibilities and the expectation that sales from Prolieve® may accelerate as a consequence. Forward-looking
statements are frequently characterized by words such as "plan," "expect," "project," "intend," "believe," "anticipate", "estimate"
and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are
based on the opinions and estimates of management at the date the statements are made. Such forward-looking statements and
forward-looking information involve known and unknown risks, uncertainties and other factors that may cause the actual results
events or developments to be materially different from any future results, events or developments expressed or implied by such
forward-looking statements or forward-looking information. These factors should be considered carefully and readers are cautioned
not to place undue reliance on such forward-looking statements and forward-looking information. Except as required by applicable
securities laws, the Company disclaims any obligation to update any such factors or to publicly announce the results of any
revisions to any of the forward-looking statements or forward-looking information contained herein to reflect future results,
events or developments.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more details, please visit:
www.medifocusinc.com
www.prolieve.com
www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627
Medifocus, Inc. Tel: 410-290-5734
SOURCE: Medifocus, Inc.
